# Targeting Cadherin-11 for the Treatment of Calcific Aortic Valve Disease

> **NIH NIH F32** · VANDERBILT UNIVERSITY · 2021 · $46,318

## Abstract

Project Summary
Calcific aortic valve disease (CAVD) is the most common affliction of the cardiac valves and is becoming more
prevalent in aging populations. It is a notoriously difficult disease to study and treat, and is responsible for
approximately 15,000 deaths per year in North America. Currently, the only effective, long-term treatments for
CAVD are surgical or transcatheter aortic valve replacements; however, these replacements are only
recommended for patients with severe aortic stenosis or in patients undergoing surgery for another form of
heart disease. There is no preventative therapy or pharmacological intervention to treat CAVD as the
mechanisms underlying this disease’s progression are poorly understood. Our lab has implicated the cell-cell
adhesion protein cadherin-11 (CDH11) in this disease and shown that blocking this protein with a monoclonal
antibody prevents every aspect of CAVD. While this antibody provides hope, it is not clinically translatable, as it
would require asymptomatic patients to receive monthly injections to prevent a disease that can take years to
present. Thus, development of novel pharmaceuticals is needed to prevent this disease. Previous research
indicates that the COX2 inhibitor celecoxib binds to CDH11, but is associated with aortic stenosis in human
patients. Preliminary results from our lab indicate the inactive analog celecoxib, dimethyl celecoxib, could be a
small molecule that prevents CAVD both in vitro and in vivo as it also binds CDH11 but prevents several
hallmarks of CAVD in vitro. Additionally, analysis of the structural similarities between celecoxib and dimethyl
celecoxib indicate that sulfonamides could be a useful class of small molecules for targeting CDH11. The goal
of this study is to identify CDH11-binding small molecules that block the progression of CAVD and determine
the disease mechanisms that are altered in vitro when these drugs are administered. We present two primary
aims: 1) determine the efficacy of dimethyl celecoxib as a therapeutic for CAVD in vivo and 2) identify novel
CDH11 binding compounds through the use of high-throughput, small molecule screening. This study will be
the first to demonstrate the effectiveness of small molecules in preventing CAVD and will provide insight into
the mechanisms that cause this disease.

## Key facts

- **NIH application ID:** 10328482
- **Project number:** 5F32HL154596-02
- **Recipient organization:** VANDERBILT UNIVERSITY
- **Principal Investigator:** Lance Riley
- **Activity code:** F32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $46,318
- **Award type:** 5
- **Project period:** 2020-07-01 → 2022-03-25

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10328482

## Citation

> US National Institutes of Health, RePORTER application 10328482, Targeting Cadherin-11 for the Treatment of Calcific Aortic Valve Disease (5F32HL154596-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10328482. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*